Siewert Ⅰ型食管胃结合部腺癌淋巴结转移特点及预后分析

Characteristics of lymph node metastasis and prognostic analysis of Siewert type Ⅰ adenocarcinoma of esophagogastric junction

  • 摘要: 目的:分析SiewertⅠ型食管胃结合部腺癌(AEG)淋巴结转移特点及影响患者预后的因素。
    方法:采用回顾性病例对照研究方法。收集2008年1月至2011年5月山东大学齐鲁医院收治的87例行手术切除治疗Siewert Ⅰ型AEG患者的临床病理资料。患者均行经左胸后外侧切口行下段食管+近端胃大部切除术。清扫胸腔第107、108/110、109、111、112组淋巴结和腹腔第1/2、3、4、5、6、7、10、11组淋巴结。所有淋巴结标本送常规病理学检查。观察指标:(1)肿瘤淋巴结清扫及转移情况。(2)随访及预后情况。(3)预后因素分析指标:性别、年龄、肿瘤分化程度、肿瘤浸润深度、TNM分期、淋巴结转移。(4)对独立预后因素进行分层分析。采用电话和门诊方式进行随访。术后2年内每3个月复查1次,2年后每6个月复查1次。门诊复查血生化指标、超声、钡餐、CT,必要时行胃镜检查。了解患者生存情况。随访时间截至2016年6月。计数资料以率表示,采用χ2检验。采用KaplanMeier法绘制生存曲线并计算生存率,单因素分析采用Logrank检验,多因素分析采用COX比例风险回归模型。
    结果:(1)肿瘤淋巴结清扫及转移情况:87例Siewert Ⅰ〖KG*4〗型AEG患者中,15例无淋巴结转移,72例有淋巴结转移,淋巴结转移率为82.8%(72/87)。清扫的胸腔淋巴结中第107、108/110、109、111、112组淋巴结转移率分别为6.9%(6/87)、27.6%(24/87)、0、4.6%(4/87)、0,5者比较,差异有统计学意义(χ2=63.301,P<0.05)。清扫的腹腔淋巴结中第1/2、3、4、5、6、7、10、11组淋巴结转移率分别为52.9%(46/87)、32.2%(28/87)、10.3%(9/87)、0、0、47.1%(41/87)、0、0,8者比较,差异有统计学意义(χ2=215.096, P<0.05),其中第1/2组和第7组淋巴结转移率均显著高于第3组(χ2=7.618,4.059,P<0.05),第1/2组和第7组淋巴结转移率比较,差异无统计学意义(χ2=0.575,P>0.05)。(2)随访及预后情况:87例Siewert Ⅰ型AEG患者均获得随访,随访时间为17~102个月,中位随访时间为45个月。87例Siewert Ⅰ型AEG患者1、3、5年生存率分别为100.0%、69.0%、34.5%。(3)预后因素分析:单因素分析结果显示:肿瘤分化程度、肿瘤浸润深度、TNM分期、淋巴结转移是影响Siewert Ⅰ型AEG患者预后的相关因素(χ2=7.565,7.436,9.377,6.164,P<0.05)。多因素分析结果显示:肿瘤分化程度为低分化和TNM分期为Ⅲ期是影响Siewert Ⅰ型AEG患者预后不良的独立危险因素(RR=0.448,3.507,95%可信区间:0.272~0.738,1.116~11.022,P<0.05)。(4)分层分析:7例高分化Siewert Ⅰ型AEG患者中位生存时间为62个月,1、3、5年生存率分别为100.0%、100.0%、71.4%;37例中分化AEG患者中位生存时间为52个月,1、3、5年生存率分别为100.0%、86.5%、37.8%;43例低分化AEG患者中位生存时间为36个月,1、3、5年生存率分别为100.0%、51.2%、25.6%,3者生存情况比较,差异有统计学意义(χ2=7.565,P<0.05)。27例TNM Ⅰ~Ⅱ期Siewert Ⅰ型AEG患者中位生存时间为66个月,1、3、5年生存率分别为100.0%、85.2%、59.3%;60例TNM Ⅲ期Siewert Ⅰ型AEG患者中位生存时间为34个月,1、3、 5年生存率分别为100.0%、70.0%、23.3%;两者生存情况比较,差异有统计学意义(χ2=9.377,P<0.05)。
    结论:Siewert Ⅰ型AEG患者术中胸部重点清扫第107、108、110组淋巴结,腹部重点清扫第1、2、3、7组淋巴结。肿瘤分化程度为低分化和TNM分期为Ⅲ期是影响Siewert Ⅰ型AEG患者预后不良的独立危险因素。

     

    Abstract: Objective:To analyze the characteristics of lymph node metastasis and prognostic factors of Siewert type Ⅰ adenocarcinoma of esophagogastric junction (AEG).
    Methods:The retrospective casecontrol study was conducted. The clinicopathological data of 87 patients with Siewert type Ⅰ AEG who were admitted to the Qilu Hospital of Shandong University between January 2008 and May 2011 were collected. All the patients underwent lower esophageal and proximal subtotal gastrectomy via left and posterior thoracic incision. No. 107, 108/110, 109, 111, 112 thoracic lymph nodes and No.1/ 2, 3, 4, 5, 6, 7, 10, 11 abdominal lymph nodes were dissected. All the specimens of lymph nodes were detected by pathological examination. Observation indicators included: (1) lymph node dissection and metastasis, (2) followup and prognosis, (3) indexes of prognostic factors analysis: gender, age, tumor differentiation, depth of tumor invasion, TNM stage and lymph node metastasis, (4) stratified analysis of independent prognostic factors. Followup using telephone interview and outpatient examination was performed to detect the survival of patients up to June 2016. Patients were reexamined by blood biochemistry, ultrasound, barium meal, computed tomography (CT) and gastroscopy (if necessary)every 3 months within 2 years postoperatively and every 6 months after 2 years. Count data were represented as ratio and analyzed using the chisquare test. The survival curve and survival rate were respectively drawn and calculated by KaplanMeier method. The univariate and multivariate analyses were done using the Logrank test and COX regression model, respectively.
    Results:(1) Lymph node dissection and metastasis: of the 87 patients with Siewert type Ⅰ AEG, 15 didn′t have lymph node metastasis and 72 had lymph node metastasis, with a metastasis rate of 82.8% (72/87). Metastasis rates of No.107, 108/110, 109, 111 and 112 thoracic lymph nodes were respectively 6.9%(6/87), 27.6% (24/87), 0, 4.6% (4/87) and 0, with a significant difference (χ2=63.301, P<0.05). Metastasis rates of No.1/ 2, 3, 4, 5, 6, 7, 10 and 11 abdominal lymph nodes were respectively 52.9%(46/87), 32.2%(28/87), 10.3% (9/87), 0, 0, 47.1%(41/87), 0 and 0, with a significant difference (χ2=215.096, P<0.05) . Metastasis rates of No.1/ 2 and No.7 abdominal lymph nodes were significantly higher than that of No.3 of abdominal lymph nodes (χ2=7.618, 4.059, P<0.05), and there was no significant difference in metastasis rate between No.1/2 and No.7 abdominal lymph nodes (χ2=0.575, P>0.05). (2)Followup and prognosis: 87 patients were followed up for 17-102 months with a median time of 45 months. The 1, 3, 5year survival rates of 87 patients were 100.0%, 69.0% and 34.5%, respectively. (3) Analysis of prognostic factors: results of univariate analysis showed that tumor differentiation, depth of tumor invasion, TNM stage and lymph node metastasis were related factors affecting the prognosis of patients with Siewert type Ⅰ AEG (χ2=7.565, 7.436, 9.377, 6.164, P<0.05). Results of multivariate analysis showed that lowdifferentiated tumor and stage Ⅲ of TNM stage were independent risk factors affecting poor prognosis of patients with Siewert type Ⅰ AEG (RR=0.448, 3.507, 95% confidence interval: 0.272-0.738, 1.116-11.022, P<0.05). (4) Stratified analysis: median survival time, 1, 3, 5year survival rates were 62 months, 100.0%, 100.0%, 71.4% in 7 patients with highdifferentiated Siewert type ⅠAEG and 52 months, 100.0%, 86.5%, 37.8% in 37 patients with moderatedifferentiated Siewert type ⅠAEG and 36 months, 100.0%, 51.2%, 25.6% in 43 patients with lowdifferentiated Siewert type Ⅰ AEG, respectively, showing a significant difference in survival (χ2=7.565, P<0.05). Median survival time, 1, 3, 5year survival rates were 66 months, 100.0%, 85.2%, 59.3% in 27 patients with Siewert type Ⅰ AEG in stage Ⅰ-Ⅱ of TNM stage and 34 months, 100.0%, 70.0%, 23.3% in 60 patients with Siewert type Ⅰ AEG in stage Ⅲ of TNM stage, respectively, showing a significant difference in survival (χ2=9.377, P<0.05).
    Conclusions:No.107, 108, 110 thoracic lymph nodes dissection and No.1, 2, 3, 7 abdominal lymph node dissection should be emphasized. Lowdifferentiated tumor and stage Ⅲ of TNM stage are independent risk factors affecting poor prognosis of patients with Siewert type Ⅰ AEG.

     

/

返回文章
返回